Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Pain and Therapy|May 2, 2025
Adverse Reactions Following First-Dose Administration of Co-Crystal of Tramadol-Celecoxib Versus Tramadol Alone for Moderate-To-Severe Acute PainAdelaida Morte, Mariano Sust, Anna Vaqué, et al.Arzneimittel-Forschung|October 28, 2011
Bioequivalence evaluation of two oral formulations of quetiapine fumarate in healthy volunteersMercedes Cánovas, Ferran Torres, Gema Domenech, et al.Arzneimittel-Forschung|March 25, 2011
Bioequivalence evaluation of two dosage forms of olanzapine 10 mg formulations in healthy volunteersMercedes Cánovas, Ferran Torres, Gema Domenech, et al.Drugs in R&D|June 14, 2024
Efficacy of Co-Crystal of Tramadol-Celecoxib (CTC) in Patients with Acute Moderate-to-Severe Pain: A Pooled Analysis of Data from Two Phase 3 Randomized Clinical TrialsRichard Langford, Eugene R Viscusi, Adelaida Morte, et al.Current Medical Research and Opinion|January 11, 2024
Co-crystal of tramadol-celecoxib (CTC) for acute moderate-to-severe painRichard Langford, Cesar Margarit, Adelaida Morte, et al.Pain and Therapy|September 24, 2024
Safety of Co-Crystal of Tramadol-Celecoxib (CTC) in Patients with Acute Moderate-to-Severe Pain: Pooled Analysis of Three Phase 3 Randomized TrialsEugene R Viscusi, Richard Langford, Adelaida Morte, et al.Clinical Therapeutics|June 25, 2021
Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability StudyJesús Cebrecos, James D Carlson, Gregorio Encina, et al.Drugs in R&D|May 2, 2013
Pharmacokinetic dose proportionality between two strengths (12.5 mg and 25 mg) of doxylamine hydrogen succinate film-coated tablets in fasting state: a single-dose, randomized, two-period crossover study in healthy volunteersSebastián Videla, Jesús Cebrecos, Mounia Lahjou, et al.European Journal of Pain (London, England)|August 17, 2022
Efficacy and safety of co-crystal of tramadol-celecoxib (CTC) in acute moderate-to-severe pain after abdominal hysterectomy: A randomized, double-blind, phase 3 trial (STARDOM2)Richard Langford, Adelaida Morte, Mariano Sust, et al.European Journal of Pain (London, England)|December 4, 2024
E-52862-A selective sigma-1 receptor antagonist, in peripheral neuropathic pain: Two randomized, double-blind, phase 2 studies in patients with chronic postsurgical pain and painful diabetic neuropathyRafael Gálvez, Victor Mayoral, Jesús Cebrecos, et al.Pageof 2